Insulet Resumes Pivotal Study of its Next-Generation Product - Omnipod, Powered by Horizon™
Summary
“We are thrilled to continue our trial,” said Dr. Trang Ly MBBS FRACP PhD, Senior Vice President, Medical Director. “We have encouraging data from our clinical work to date and overwhelmingly positive feedback from participants and investigators. Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.